September 13, 2008 -- Covering the BioBay Investor Forum 2008, Interfax reported the increasing importance of patented technologies in China biopharma, and it predicted the Yangtze River Delta would soon house the largest collection of clinical research facilities in the world. BusinessWeek published an overview of the sea turtle phenomenon. US-based Provid Pharma formed a CRO alliance with Acesys Pharmatech of China; Tianyin Pharma (OTCBB: TYNP) released very solid unaudited results for fiscal 2008; Tongjitang Chinese Medicines announced a $20 million stock buyback; China Sky One Medical said it has submitted 26 new drugs for approval; Tianyin Pharma received approval for a TCM product for asthma; Oculus began selling its Dermacyn™ wound treatment product in China; Sinovac Biotech launched the 2008-09 version of its seasonal flu vaccine, Anflu®; and Genesis Pharma booked $12 million in new orders, most of them for its new flu product. More details...
